Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.
byBenzinga Newsdesk
September 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0